Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (Targretin)

Cancer Research

Volumn 60, Issue 21, 2000, Pages 6033-6038

  Agarwal, Veena R ^a,b   Bischoff, Eric D ^a,c   Hermann, Thomas ^a   Lamph, William W ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b BAYER CORPORATION   (United States)

^c EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPSIN; BEXAROTENE; CELL PROTEIN; LIGAND; LIPOPROTEIN LIPASE; METHYLNITROSOUREA; RETINOID X RECEPTOR;

ADIPOCYTE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER REGRESSION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE INDUCTION; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; TUMOR MODEL;

ADAPTOR PROTEIN COMPLEX 2; ADAPTOR PROTEIN COMPLEX ALPHA SUBUNITS; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADIPOCYTES; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL DIFFERENTIATION; CELL DIVISION; CLONE CELLS; COMPLEMENT FACTOR D; FEMALE; GENE EXPRESSION; GROWTH INHIBITORS; LIGANDS; LIPOPROTEIN LIPASE; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; SERINE ENDOPEPTIDASES; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0034326254     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients
2. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
3. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer
4. 'Studies on the estrogen receptor in breast cancer' - 20 years as a target for the treatment and prevention of cancer
5. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen
6. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
7. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids
8. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma
9. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure
10. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
11. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimers: Intermolecular synergy requires only the PPARγ hormone-dependent activation function
12. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
13. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
14. Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas
15. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas
16. The sequence of cDNA encoding lipoprotein lipase. A member of a lipase gene family
17. Differentiation-induced gene expression in 3T3-L1 preadipocytes. Characterization of a differentially expressed gene encoding stearoyl-CoA desaturase
18. Molecular cloning and sequencing of cDNAs encoding the entire rat fatty acid synthase
19. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice
20. Genomic sequencing
21. The primary structure of rat ribosomal proteins P0, P1, and P2 and a proposal for a uniform nomenclature for mammalian and yeast ribosomal proteins
22. Rat peroxisome proliferator-activated receptors and brown adipose tissue function during cold acclimatization
23. Expression, purification, and crystallization of the adipocyte lipid binding protein
24. In vitro chemotherapy testing of transitional cell carcinoma
25. The transformation of a malignant paravertebral sympathioblastoma into a benign ganglioneuroma
26. Small doses of ARA-C in the treatment of acute myeloid leukaemia: Differentiation of myeloid leukaemia cells?
27. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A Phase II clinical trial with a differentiation-inducing agent
28. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results
29. Cytokine therapeutics: Lessons from interferon α
30. Mechanism of interferon action in hairy cell leukemia: A model of effective cancer biotherapy
31. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
32. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
33. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia
34. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study
35. The efficacy of 9-cis retinoic acid in experimental models of cancer
36. The RXR heterodimers and orphan receptors
37. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor